Although further studies are required to fully understand the regulatory mechanisms of FGF9 expression, our data would help understand the NASH-specific activation status of fibroblasts and its pathogenic role in the development of HCC. The gene discussed is FGF9; the disease is metabolic dysfunction-associated steatohepatitis.